title: Is there a role for maraviroc to treat HIV-associated central nervous system white matter disease?
authors.affiliation: King's College Hospital NHS Foundation Trust, London, UK.
authors.forename: Colin
authors.initials: C
authors.lastname: Ball
authors.forename: Malur
authors.initials: M
authors.lastname: Sudhanva
authors.forename: Jozef
authors.initials: J
authors.lastname: Jarosz
authors.forename: Frank A
authors.initials: FA
authors.lastname: Post
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Hamlyn
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003510:Cyclohexanes / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D056784:Leukoencephalopathies / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000077592:Maraviroc; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D003510:Cyclohexanes; D014230:Triazoles; D000077592:Maraviroc